C
hronic kidney disease (CKD) is nearly always asymptomatic in its early stages (1) . The most commonly accepted definition of CKD was developed by Kidney Disease: Improving Global Outcomes (KDIGO) (2) and the Kidney Disease Outcomes Quality Initiative (KDOQI) (3) as abnormalities of kidney structure or function, present for more than 3 months, with implications for health. Criteria for CKD include markers of kidney damage (albuminuria, as indicated by an albumin excretion rate of 30 mg/24 h or greater and an albumin-creatinine ratio of 3 mg/mmol or greater [Ն30 mg/g]); urine sediment abnormalities; electrolyte and other abnormalities due to tubular disorders; abnormalities detected by histologic examination; structural abnormalities detected by imaging; history of kidney transplantation or presence of kidney damage; or kidney dysfunction that persists for 3 or more months, as shown by structural and functional abnormalities (most often based on increased albuminuria, as indicated by a urinary albumin-creatinine ratio of 3 mg/mmol or greater [Ն30 mg/g]) or a glomerular filtration rate (GFR) less than 60 mL/min/1.73 m 2 for 3 or more months. Traditionally, CKD is categorized into 5 stages that are based on disease severity defined by GFR (3) ( Table 1) ; stages 1 to 3 are considered to be early-stage CKD. People with early stages of the disease are typically asymptomatic, and the diagnosis is made by using laboratory tests or imaging. In 2013, KDIGO revised CKD staging to consider both 5 stages of GFR as well as 3 categories of albuminuria to define CKD severity (2) . Approximately 11.1% (22.4 million) of adults in the United States have stage 1 to 3 CKD, and prevalence appears to be increasing, especially for stage 3 CKD (4, 5) . Approximately one half of persons with CKD have either stage 1 or 2 CKD (increased albuminuria with normal GFR), and one half have stage 3 CKD (low GFR, with one third of these individuals having increased albuminuria and two thirds having normal albuminuria) (5) . The prevalence of CKD is slightly higher in women than in men (12.6% vs. 9.7%) (6) .
Stage 1 to 3 CKD, reduced GFR, and albuminuria are associated with mortality (7, 8) , cardiovascular disease (9), fractures (10), bone loss (11) , infections (12) , cognitive impairment (13) , and frailty (14) . Treatment of stage 1 to 3 CKD involves treating associated conditions and complications. Many patients with CKD may already be taking medications targeting comorbid conditions, such as hypertension, cardiovascular disease, and diabetes.
This American College of Physicians (ACP) guideline presents available evidence on the screening, monitoring, and treatment of stage 1 to 3 CKD. Clinicians are the target audience. The target patient population for screening is adults, and the target population for treatment it is adults with stage 1 to 3 CKD.
METHODS
This guideline is based on a systematic evidence review sponsored by the Agency for Healthcare Research and Quality (AHRQ) (15) and conducted by the Minnesota Evidence-based Practice Center (6) that addressed the following key questions:
1. In asymptomatic adults with or without recognized risk factors for CKD incidence, progression, or complica The literature search identified randomized, controlled trials and controlled clinical trials published in English from 1985 through November 2011, by using MEDLINE and the Cochrane Database of Systematic Reviews and review of reference lists of relevant articles and articles suggested by experts. Details of the evidence review methods are available in the full AHRQ report (6) .
This guideline rates the recommendations by using the ACP's guideline grading system (Table 2) (16) .
RISK FACTORS FOR CKD
The major risk factors for CKD include diabetes, hypertension, and cardiovascular disease. Other risk factors include older age; obesity; family history; and African American, Native American, or Hispanic ethnicity. Diabetes is more prevalent in patients with stage 1 to 3 CKD (20%) than in patients without CKD (5%) (17). Hypertension is also more prevalent in patients with CKD (64% in stage 3 and 36% in stage 1) than in patients without CKD (24%) (17). The prevalence of cardiovascular disease increased from 6% in patients without CKD to 36% in those with stage 3 CKD (17).
SCREENING FOR CKD

Benefits of Screening Direct Evidence
No randomized, controlled trials that compared the effect of systematic CKD screening versus no CKD screening on clinical outcomes were identified.
Indirect Evidence
Prevalence. Among U.S. adults older than 20 years, 11.1% have stage 1 to 3 CKD. Approximately 5% of adults younger than 52 years and without diabetes, hypertension, or obesity have CKD, compared with 68% older than 81 years (17). Most patients with stage 1 to 3 CKD are not clinically recognized to have CKD (18, 19) .
Adverse Health Consequences. Although stage 1 to 3 CKD is usually asymptomatic, it is associated with mortality (7, 8) , cardiovascular disease (9), fractures (10), bone Clinical Guideline Screening, Monitoring, and Treatment of Stage 1 to 3 CKD loss (11) , infections (12) , cognitive impairment (13) , and frailty (14) .
Validity and Reliability of Screening Tests. No population-based studies have tested the sensitivity or specificity of 1-time CKD screening using either estimated GFR or albuminuria or the validity and reliability of repeated screening. Serum creatinine is measured by using a simple blood test. Although no studies have compared GFR estimated from serum creatinine values with direct GFR measurement, estimation is believed to be reasonably accurate (20) . There are many sources of variability when measuring urinary albumin loss (21) , and the method of collection and measurement of urinary albumin and creatinine has yet to be standardized.
Effect of Treatments on Screen-Detected CKD. There was no randomized trial evidence evaluating the effectiveness of treatment on clinical outcomes of CKD identified through screening.
Harms of Screening Direct Evidence
No randomized, controlled trials have evaluated the harms of systematic CKD screening.
Indirect Evidence
Expert opinion suggests that the harms of CKD screening include misclassification of patients owing to false-positive test results, adverse effects of unnecessary testing, psychological effects of being labeled with CKD, adverse events associated with pharmacologic treatment changes after CKD diagnosis, and possible financial ramifications of CKD diagnosis.
MONITORING FOR CKD
Benefits of Monitoring Direct Evidence
No randomized, controlled trials have evaluated clinical outcomes for patients with stage 1 to 3 CKD who were systematically monitored for worsening kidney function versus no CKD monitoring, usual care, or an alternative CKD monitoring regimen.
Indirect Evidence
Frequency of Worsening of Kidney Function or Damage in Patients
With Stage 1 to 3 CKD. The mean annual GFR decline in patients with CKD varies widely, ranging from approximately 1 to greater than 10 mL/min/1.73 m 2 (3). Annual rates of conversion from microalbuminuria to macroalbuminuria range from 2.8% to 9% (22) (23) (24) (25) (26) (27) . Factors that have been shown to predict faster decline in GFR include diabetes, proteinuria, hypertension, older age, obesity, dyslipidemia, smoking, male sex, and cause of primary kidney disease.
Association of CKD Progression With Adverse Health Consequences. No studies longitudinally assessed the risk for adverse health outcomes in patients with worsening CKD.
A meta-analysis of prospective cohort studies reported risk for all-cause and cardiovascular mortality for different GFRs and degrees of albuminuria (8) . Patients with albuminuria and GFR greater than 60 mL/min/1.73 m 2 (CKD stage 1 or 2) had a higher mortality risk if they had macroalbuminuria compared with microalbuminuria, although lower GFR within this range was not associated with a higher mortality risk. Mortality risk was increased in patients with a GFR of 45 to 59 mL/min/1.73 m 
Validity and Reliability of Tests to Monitor CKD
Progression. The same tests are used both to screen for CKD and monitor its progression. No studies assessed the accuracy, precision, specificity, or sensitivity of estimating GFR over time or for detecting a change in CKD stage on the basis of GFR category. The lack of consistent reproducibility in albuminuria measurements causes concern about the ability of longitudinal albuminuria measurements to accurately represent CKD progression.
Effect of Treatments on Clinical Outcomes in Patients Whose CKD Has Progressed.
Evidence is lacking on whether treatments reduce the risk for adverse clinical outcomes in patients with worsening CKD.
Harms of Monitoring Direct Evidence
No randomized, controlled trials were identified that compared the adverse effects of systematic monitoring of stage 1 to 3 CKD versus no CKD monitoring, usual care, or an alternative CKD monitoring regimen.
Indirect Evidence
Expert opinion suggests that the harms of monitoring for CKD progression include incorrect reclassification of patients, adverse effects of unnecessary testing, labeling effects, adverse events associated with changes in pharmacologic treatments after testing, and possible financial ramifications of a more advanced CKD diagnosis. Insufficient evidence to determine net benefits or risks *Adopted from the classification developed by the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) workgroup. , although most of the data were derived from a large study that showed no difference in mortality between patients with and without microalbuminuria (43). Therapy with ACE inhibitors did not reduce the risk for cardiovascular mortality, myocardial infarction (MI), stroke, or other vascular outcomes.
TREATMENT OF CKD
ACE Inhibitors Versus ␤-Blockers. Low-quality evidence showed no difference in the risk for ESRD or allcause mortality, cardiovascular mortality, stroke, or heart failure between patients treated with ACE inhibitor monotherapy compared with ␤-blocker monotherapy (44 -46) ( Table 3) .
ACE Inhibitors Versus Diuretics. Low-quality evidence showed no difference between ACE inhibitor-treated and diuretic-treated patients in terms of risk for ESRD (47) ( Table 3) . Evidence was insufficient evidence to determine whether the treatments alter the all-cause mortality risk. There was no statistically significant difference between the 2 treatments in risk for stroke or multiple composite cardiovascular outcomes.
ACE Inhibitors Versus Angiotensin II-Receptor Blockers. End-stage renal disease outcomes were not reported in studies comparing ACE inhibitor monotherapy with angiotensin II-receptor blocker (ARB) monotherapy. Low-quality evidence showed that there was no difference between these 2 monotherapies in risk for all-cause mortality (36, 48 -51) ( Table 3 ). There was no statistically significant difference between the 2 treatments for other reported clinical vascular or renal outcomes.
ACE Inhibitors Versus Calcium-Channel Blockers. Lowquality evidence showed that there was no difference in the risk for ESRD (47, 52, 53) or all-cause mortality (23, (52) (53) (54) (55) (56) between ACE inhibitor monotherapy and calciumchannel blocker monotherapy ( Table 3) . There was also no difference between the 2 treatments in terms of risk for cardiovascular mortality, stroke, congestive heart failure (CHF), or any composite vascular end point.
ACE Inhibitors Versus Non-ACE Inhibitor Antihypertensive Therapy. Low-quality evidence showed that ACE inhibitor monotherapy did not statistically significantly reduce the risk for ESRD compared with non-ACE inhibitor antihypertensive therapy (calcium antagonists, ␤-blockers, or ␣-adrenoblockers) (57) ( Table 3 ). Evidence was insufficient that ACE inhibitor therapy compared with non-ACE inhibitor antihypertensive therapy is associated with a reduced risk for all-cause mortality.
ARB Monotherapy Versus Placebo. High-quality evidence showed that treatment with ARBs reduced the risk for ESRD in patients with stage 1 to 3 CKD (RR, 0.77 [CI, 0.66 to 0.90]) compared with placebo (58 -60). However, it was not possible to determine whether risk was also reduced in patients with microalbuminuria or impaired GFR who do not have diabetes and hypertension (58 -60). High-quality evidence showed that treatment with ARBs did not reduce the risk for all-cause mortality compared with placebo (58 -61) ( Table 3) . Treatment with ARBs did not reduce the risk for cardiovascular mortality, MI, CHF complications, or any other clinical vascular outcome compared with placebo; however, ARB treatment did statistically significantly improve renal outcomes.
ARBs Versus Calcium-Channel Blockers. Low-quality evidence showed that ARB monotherapy did not reduce the risk for ESRD (59) or all-cause mortality (59, 62) compared with calcium-channel blocker monotherapy ( Table  3) . There was also no statistically significant difference between the 2 treatments in terms of risk for stroke, cardiovascular mortality, CHF, or composite vascular end points.
␤-Blockers Monotherapy Versus Placebo. End-stage renal disease outcomes were not reported in studies comparing ␤-blocker monotherapy with placebo. Moderatequality evidence showed that treatment of CKD with a ␤-blocker reduced the risk for all-cause mortality compared with placebo (RR, 0.73 [CI, 0.65 to 0.82]) (63) (64) (65) (66) . ␤-Blocker treatment also statistically significantly reduced the risk for cardiovascular mortality (64, 66) , CHF hospitalization (65, 66) , and CHF death (65, 66) .
Calcium-Channel Blockers Versus Placebo. Low-quality evidence showed that treatment with calcium-channel blockers in mostly hypertensive patients with albuminuria did not reduce the risk for ESRD (59) or all-cause mortality (23, 59) compared with placebo, although this treatment did reduce the risk for MI (23, 59) (Table 3) . There was no statistically significant reduction in composite renal outcomes.
Calcium-Channel Blockers Versus ␤-Blockers. Lowquality evidence showed that calcium-channel blocker monotherapy did not statistically significantly reduce the ACE ϭ angiotensin-converting enzyme; ARB ϭ angiotensin II-receptor blocker; CHF ϭ congestive heart failure; CKD ϭ chronic kidney disease; CVD ϭ cardiovascular disease; ESRD ϭ end-stage renal disease; MI ϭ myocardial infarction; NA ϭ not applicable; NR ϭ not reported; RCT ϭ randomized, controlled trial; RRϭ relative risk. * Adverse events were sparsely reported in the trials included in this study and often similar in control and treatment groups. † Data derived from a study comparing ACE inhibitor plus ARB combination therapy with either ARB or ACE inhibitor monotherapy. Table 3) . No statistically significant difference in renal outcomes was reported.
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Calcium-Channel Blockers Versus Diuretics.
Lowquality evidence showed that calcium-channel blocker monotherapy did not statistically significantly reduce the risk for ESRD compared with diuretic monotherapy (47) ( Table 3) . Mortality data were not reported. There were no statistically significant differences in renal or vascular outcomes reported.
Thiazide Diuretics Versus Placebo. No renal outcomes were reported for the comparison of thiazide diuretic monotherapy with placebo. Low-quality evidence showed no difference between the 2 groups in risk for all-cause mortality (69) ( Table 3) . Diuretic monotherapy statistically significantly reduced the risk for stroke and 1 composite vascular outcome.
Combination Therapy Versus Monotherapy
ACE Inhibitors Plus ARBs Versus ACE Inhibitors
Alone. Low-quality evidence showed no statistically significant difference in risk for ESRD between treatment with ACE inhibitors plus ARBs compared with ACE inhibitors alone (70) ( Table 3) . Moderate-quality evidence also showed no statistically significant difference in the risk for all-cause mortality in the combined treatment group compared with monotherapy (50, 71, 72) ( Table 3) .
ACE Inhibitors Plus ARBs Versus ARBs
Alone. There was no evidence directly comparing the risk for ESRD or mortality with ACE inhibitors plus ARBs compared with ARB monotherapy. However, 1 trial (60) compared ACE inhibitor plus ARB combination therapy with either ARB or ACE inhibitor monotherapy (results for monotherapy reported together); moderate-quality evidence showed no reduced risk for ESRD, and low-quality evidence showed no reduced risk for all-cause mortality in the combined treatment group (Table 3) .
Other Comparisons. Evidence was insufficient to determine the effect of the following comparisons on ESRD or mortality: ACE inhibitors plus calcium-channel blockers versus ACE inhibitor monotherapy or calcium-channel blocker monotherapy; ACE inhibitors plus diuretics versus ACE inhibitor monotherapy; and ACE inhibitors plus diuretics versus placebo.
Combination Therapy Versus Combination Therapy
Evidence was insufficient to determine the effect of the following comparisons on ESRD or mortality: ACE inhibitor plus ARB versus ACE inhibitor plus aldosterone antagonist; ACE inhibitor plus diuretic versus ACE inhibitor plus calcium-channel blocker; ACE inhibitor plus aldosterone antagonist versus ACE inhibitor plus placebo; and ACE inhibitor and ARB plus aldosterone antagonist versus ACE inhibitor and ARB plus placebo.
Strict Versus Standard Blood Pressure Control
Seven studies (46, (73) (74) (75) (76) (77) (78) randomly assigned patients with stage 1 to 3 CKD (mostly with hypertension) to strict versus standard blood pressure targets, and medications varied among studies. The mean achieved blood pressure ranged from 128 to 133 mm Hg systolic and 75 to 81 mm Hg diastolic in the strict-control group versus 134 to 141 mm Hg systolic and 81 to 87 mm Hg diastolic in the standard-control group. Low-quality evidence showed no difference in risk for ESRD (46, 75, 78) or all-cause mortality (46, 75, 77, 78) . between strict and standard blood pressure control ( Table 3 ). There was no statistically significant difference between other reported vascular or renal outcomes.
Non-Blood Pressure Control Interventions Statins Versus Control
Low-quality evidence showed that treatment with statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) did not reduce the risk for ESRD in patients with dyslipidemia and stage 1 to 3 CKD (79, 80) ( Table  3) . Moderate-quality evidence (subgroup analyses) showed that statins reduced the risk for all-cause mortality in patients with dyslipidemia as well as stage 1 to 3 CKD (RR, 0.81 [CI, 0.71 to 0.94]) (29, 79, (81) (82) (83) (84) (85) (86) (87) . Statins were found to statistically significantly reduce the risk for MI, stroke, and most composite vascular outcomes reported.
Low-quality evidence from 1 trial (88) that reported on mortality in patients with CKD and dyslipidemia treated with high-dose atorvastatin (80 mg/d) versus lowdose atorvastatin (10 mg/d) found no difference in the risk for all-cause mortality (7.0% vs. 7.5%, respectively; RR 0.93 [CI, 0.72 to 1.20]); however, the high-dose atorvastatin group had a decreased risk for CHF hospitalization and composite vascular outcomes. Another study (89) reported no differences between high-and low-dose statin treatment in terms of composite vascular outcomes. No results were reported for ESRD or any renal outcomes.
Gemfibrozil Versus Placebo or Control
Low-quality evidence from a single trial (90) supports no difference in all-cause mortality reduction for treatment with the triglyceride-lowering medication gemfibrozil compared with placebo (RR, 0.91 [CI, 0.52 to 1.62]). No individuals in the study experienced ESRD. Gemfibrozil was found to statistically significantly reduce the risk for the composite outcome of fatal coronary heart disease, nonfatal MI, or stroke compared with placebo. Evidence was insufficient to determine whether treatment with gemfibrozil reduced the risk for ESRD or all-cause mortality compared with a triglyceride-lowering diet (91).
Low-Protein Diet Versus Usual-Protein Diet
Low-quality evidence from 3 trials comparing a lowprotein diet with usual diet in patients with stage 1 to 3 CKD (92-94) showed no statistically significant difference (Table 3) , and data from 4 trials (93) (94) (95) (96) showed no statistically significant difference in the risk for all-cause mortality ( Table 3) .
Intensive Diabetes Control Versus Usual Care
Evidence was insufficient to determine whether intensive glycemic control in patients with type 1 or type 2 diabetes improved the risk for ESRD or all-cause mortality.
Intensive Multicomponent Treatment Versus Usual Care
Low-quality evidence showed no reduced risk in ESRD (97-100) or all-cause mortality (97) (98) (99) (100) (101) between the intensive multicomponent treatment and usual care ( Table 3) .
HARMS OF TREATMENT STRATEGIES FOR STAGE 1 TO 3 CKD
Most of the trials did not report adverse events, and those reported were similar for patients with CKD and other patients treated with the same drugs. The most commonly reported adverse event with ACE inhibitor treatment was cough. Therapy with ARBs was associated with statistically significantly increased hyperkalemia (3.2% vs. 1.3% with placebo; RR, 2.38 [CI, 1.57 to 3.61]). Adverse events associated with ␤-blocker therapy included heart failure, fatigue, bradycardia, dizziness, and hypotension. One trial (60) reported that ACE inhibitor plus ARB was associated with statistically significantly increased risk for cough, hyperkalemia, hypotension, and acute kidney failure requiring dialysis (RR, 1.95 [CI, 1.09 to 3.49]) compared with ACE inhibitor monotherapy. No adverse events were reported for other therapies included in the review.
SUMMARY
No randomized, controlled trials evaluated the benefits and harms of screening for stage 1 to 3 CKD. Benefit of screening would be derived from the anticipated benefits of treatment. No studies tested the sensitivity and specificity of 1-time screening in the general population using estimated GFR or albuminuria for diagnosis of CKD. There was no evidence evaluating the benefits of early treatment on clinical outcomes of patients with CKD who were identified through screening. Potential harms of screening include labeling, adverse effects of unnecessary tests and treatments, and financial ramifications.
No randomized, controlled trials evaluated the benefits and harms of monitoring patients with stage 1 to 3 CKD for disease progression. Rates of annual GFR decline vary, and lower GFR rates have been associated with increased mortality risk. Because there is considerable individual variability in albuminuria measurements, there are concerns about the accuracy of longitudinal measurement for CKD progression. Also, evidence evaluating the validity and reliability of the monitoring tests is lacking. Potential harms of monitoring for CKD progression are the same as those for screening.
Many patients, regardless of CKD status, are already taking ACE inhibitors, ARBs, statins, or other drugs to treat existing comorbid conditions. Monotherapy with ACE inhibitors or ARBs statistically significantly reduced the risk for ESRD in patients with CKD, but benefits were limited to patients with macroalbuminuria, and most of these patients also had diabetes and hypertension. No studies showed that treatment with other drug monotherapy statistically significantly reduced the risk for ESRD. Treatment with statins reduced the risk for mortality, MI, and stroke in patients with hyperlipidemia. ␤-Blocker therapy also reduced the risk for mortality, MI, and CHF, although most of the patients included in the studies were already being treated with ACE inhibitors or ARBs. Calcium-channel blockers, diuretics, a low-protein diet, intensive diabetes control, and intensive multicomponent interventions did not reduce the risk for ESRD or all-cause mortality compared with placebo or control.
None of the combination therapies were shown to have a beneficial effect on reducing the risk for ESRD or all-cause mortality compared with monotherapy. Evidence was insufficient to determine the efficacy of various combination therapies compared with other combination therapies for reducing risk for ESRD or all-cause mortality.
Harms of pharmacologic treatments were not generally reported specifically for patients with patients and were similar to adverse effects experienced by all other patients treated with the same drug ( Table 3) .
The Figure summarizes the recommendations.
RECOMMENDATIONS
Recommendation 1: ACP recommends against screening for chronic kidney disease in asymptomatic adults without risk factors for chronic kidney disease. (Grade: weak recommendation, low-quality evidence)
Screening is recommended when it improves important clinical outcomes while limiting harms for screened individuals. Screening for CKD does not meet these generally accepted criteria for population-based screening (102) . Although prevalence increases with age, CKD has a relatively low prevalence in the general population without risk factors. The accuracy of available screening measures for CKD or its progression is uncertain. No available evidence evaluates the sensitivity and specificity of various screening tests in the general population. Albuminuria and serum creatinine-derived estimated GFR are widely available in primary care settings, with a high sensitivity and high specificity for 1-time measures of renal damage or dysfunction, but the risk for false-positive results is also very high (5, 103, 104) .
There was no evidence evaluating the benefits of early treatment in patients identified by screening. In contrast, harms, including false-positive results, disease labeling, and Clinical Guideline Evidence showed that treatment with ACE inhibitors (moderate-quality) or ARBs (high-quality) reduces the risk for ESRD in patients with stage 1 to 3 CKD. These medications also reduced composite renal outcomes, the risk for doubling of serum creatinine, and the progression from microalbuminuria to macroalbuminuria. Head-to-head trials revealed no difference in outcomes with ACE inhibitors or ARBs. The harms of ACE inhibitors include cough, angioedema, hyperkalemia, rash, loss of taste, and leukopenia. The harms of ARBs include hyperkalemia, angioedema, and dizziness.
The current evidence did not show any benefit of combination therapy with an ACE inhibitor plus an ARB compared with monotherapy with ACE inhibitors or ARBs. In addition, the risk for adverse effects significantly increased with ACE inhibitor plus ARB combination therapy, including cough, hyperkalemia, hypotension, and acute kidney failure requiring dialysis.
Evidence revealed no difference in ESRD or mortality between strict blood pressure control (128 to 133/75 to 81 mm Hg) and standard control (134 to 141/81 to 87 mm Hg). High-quality evidence showed that statins reduced the risk for all-cause mortality. Evidence also showed that statins lower the risk for MI, stroke, and most cardiovascular outcomes in patients with stage 1 to 3 CKD. Patients included in the studies had mean low-density lipoprotein levels of 142 mg/dL (range, 109 to 192 mg/dL).
Two recently published systematic reviews not included in the AHRQ report also showed benefits of lipidlowering therapy or statin therapy in patients with CKD (105, 106) . One study showed that statin therapy decreased mortality and cardiovascular events in patients with stage 1 to 3 CKD (105) , and the other study showed that lipid-lowering therapy (including statins) decreased cardiac death and atherosclerosis-mediated cardiovascular events in patients with CKD (106). Low-quality evidence showed no effect on the risk for ESRD in patients with stage 1 to 3 CKD.
INCONCLUSIVE AREAS OF EVIDENCE Screening for CKD in Asymptomatic Adults With Risk Factors
Although there are known risk factors for CKD (diabetes, hypertension, and cardiovascular disease), ACP found the current evidence insufficient to evaluate the benefits and harms of screening for CKD in asymptomatic adults with CKD risk factors.
Periodic Monitoring of Patients Diagnosed With Stage 1 to 3 CKD
No randomized, controlled trials evaluated the benefits and harms of monitoring patients with stage 1 to 3 CKD. There is a lack of evidence that modifying treatment when progression occurs improves patient outcomes. Harms also include adverse effects from follow-up tests, unnecessary testing, increased medical visits, and health care costs. Hence, ACP concluded there is no net benefit of routinely monitoring patients with stage 1 to 3 CKD, although individual monitoring could be helpful for some patients on the basis of their risk level. Examples of individual monitoring include 1) GFR to monitor progression of the disease, changes in functioning, or well-being over time; 2) monitoring blood pressure as both a cause and complication of CKD; 3) monitoring proteinuria and serum creatinine; and 4) monitoring pharmacologic medications.
ACP HIGH-VALUE CARE ADVICE
The ACP found no evidence that screening for CKD in adults without risk factors improves clinical outcomes. In addition, there is no proven benefit of screening adults who are already taking ACE inhibitors or ARBs for microalbuminuria. In the absence of evidence that screening improves clinical outcomes, testing will add costs, owing to both the screening test and to additional follow-up tests (including those resulting from false-positive findings), increased medical visits, and costs of keeping or obtaining health insurance.
IN THE CLINIC
In the Clinic is a monthly feature in Annals that focuses on practical management of patients with common clinical conditions. It offers evidence-based answers to frequently asked questions about screening, prevention, diagnosis, therapy, and patient education and provides physicians with tools to improve the quality of care. In the Clinic includes links to ACP Smart Medicine and CME quizzes offering category 1 CME credit.
For more information on In the Clinic and to read the latest issue, visit www.annals.org/intheclinic.aspx.
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